lexpress.fr
New Anti-bronchiolitis Drug, Beyfortus, Faces Misinformation Campaign
Ahead of the September 1st launch of a national prevention campaign against respiratory syncytial virus (RSV), a disinformation campaign targeting the new monoclonal antibody Beyfortus has emerged, fueled by concerns about its safety and cost-effectiveness.
- What is the main claim made by the disinformation campaign against the new anti-bronchiolitis drug Beyfortus?
- The main claim is that Beyfortus, despite showing significant effectiveness in reducing RSV-related hospitalizations in multiple studies, is an expensive, potentially toxic drug with unknown long-term effects and may increase the risk of respiratory infections. This claim is being spread to discourage parents from using the treatment.
- What evidence supports the safety and efficacy of Beyfortus, and how significant is the disinformation campaign's reach?
- A June 2025 study across France, Germany, and the UK involving over 8,000 infants showed an over 80% reduction in RSV-related hospitalization with a single Beyfortus dose. This is supported by studies from 2024 (France) and 2025 (Italy). A July 2025 meta-analysis of 27 studies confirms this, showing reduced hospitalization, ICU admissions, and lower respiratory infections. The disinformation campaign video has already reached over 68,000 views on YouTube and nearly 120,000 on X.
- How are medical authorities responding to the disinformation campaign, and what are the broader implications of this event?
- The Société française de pharmacologie et de thérapeutique (SFPT) released a "Pharmacoflash" directly addressing the misinformation, highlighting Beyfortus's safety profile based on data from over 6 million children globally. This coordinated response, including communication with the health ministry, contrasts with the challenges faced during the COVID-19 pandemic. The event underscores the need for effective countermeasures against coordinated disinformation campaigns targeting public health initiatives.
Cognitive Concepts
Framing Bias
The article frames Hélène Banoun's claims as misinformation from the outset, highlighting her association with conspiracy theories and contrasting her statements with scientific evidence and expert opinions. The headline and introduction immediately establish the narrative that Banoun is spreading false information, potentially influencing the reader's perception before presenting the details of her arguments. This framing might preemptively discredit her perspective and lead readers to dismiss her concerns without fully considering the points she raises.
Language Bias
The article uses language that subtly casts doubt on Banoun's credibility. Terms like "conspiracy theorist," "disinformation," and "irresponsible" are used to describe her and her actions. While factually accurate in terms of her associations, this choice of words colors the reader's perception of her arguments. For example, instead of 'conspiracy theorist,' a more neutral term could be 'critic of pharmaceutical industry practices.' Similarly, instead of 'disinformation,' the term 'alternative perspective' could be considered in some instances, though this should be accompanied by careful fact-checking and expert validation. The repeated use of phrases like "without foundation" further reinforces this negative portrayal.
Bias by Omission
While the article extensively presents the counterarguments to Banoun's claims, it could benefit from a more balanced inclusion of her specific concerns. While dismissing them as misinformation, it might strengthen the article to explicitly address her concerns (e.g., lack of long-term data on Beyfortus, potential side effects) and refute them with specific evidence and expert analysis. This would allow readers to assess the claims and counter-claims more thoroughly.
False Dichotomy
The article presents a clear dichotomy between Banoun's perspective and the scientific consensus. It frames the debate as a simple opposition of truth versus falsehood, potentially overlooking the complexities of the issue. There could be room to discuss the nuanced debate surrounding the benefits and risks of new medications, acknowledging uncertainties and limitations within both perspectives.
Sustainable Development Goals
The article discusses the launch of a new monoclonal antibody treatment, Beyfortus, for RSV bronchiolitis in newborns. While facing misinformation campaigns, the treatment shows significant promise in reducing hospitalization rates and severity of the illness. This directly contributes to SDG 3, ensuring healthy lives and promoting well-being for all at all ages, specifically targeting child health. Studies cited show a reduction of over 80% in hospitalization risk. The counter-campaign of misinformation actively threatens this progress by undermining public trust in the treatment and potentially leading to preventable hospitalizations and severe illness in infants.